S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
Log in

NASDAQ:BIIB - Biogen Stock Price, Forecast & News

$333.00
-1.25 (-0.37 %)
(As of 02/17/2020 11:12 AM ET)
Today's Range
$331.83
Now: $333.00
$335.40
50-Day Range
$268.85
MA: $296.66
$338.93
52-Week Range
$215.77
Now: $333.00
$374.99
Volume1.02 million shs
Average Volume2.03 million shs
Market Capitalization$57.96 billion
P/E Ratio10.58
Dividend YieldN/A
Beta1.21
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BIIB
CUSIP09062X10
Phone617-679-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$14.38 billion
Cash Flow$38.63 per share
Book Value$73.93 per share

Profitability

Net Income$5.89 billion

Miscellaneous

Employees7,400
Market Cap$57.96 billion
Next Earnings Date4/22/2020 (Estimated)
OptionableOptionable

Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.


Biogen (NASDAQ:BIIB) Frequently Asked Questions

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

How will Biogen's stock buyback program work?

Biogen announced that its Board of Directors has authorized a stock buyback program on Monday, December 23rd 2019, which authorizes the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company's board of directors believes its shares are undervalued.

How were Biogen's earnings last quarter?

Biogen Inc (NASDAQ:BIIB) announced its earnings results on Thursday, January, 30th. The biotechnology company reported $8.34 EPS for the quarter, beating the Zacks' consensus estimate of $8.02 by $0.32. The biotechnology company earned $3.67 billion during the quarter, compared to analysts' expectations of $3.51 billion. Biogen had a net margin of 40.96% and a return on equity of 46.51%. Biogen's revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $6.99 earnings per share. View Biogen's Earnings History.

When is Biogen's next earnings date?

Biogen is scheduled to release their next quarterly earnings announcement on Wednesday, April 22nd 2020. View Earnings Estimates for Biogen.

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY20 earnings guidance on Thursday, January, 30th. The company provided earnings per share (EPS) guidance of $31.50-33.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $31.98. The company issued revenue guidance of ~$14.0-14.3 billion, compared to the consensus revenue estimate of $13.85 billion.

What price target have analysts set for BIIB?

34 Wall Street analysts have issued 12-month price targets for Biogen's stock. Their forecasts range from $230.00 to $410.00. On average, they expect Biogen's stock price to reach $316.69 in the next twelve months. This suggests that the stock has a possible downside of 4.9%. View Analyst Price Targets for Biogen.

What is the consensus analysts' recommendation for Biogen?

34 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 3 sell ratings, 20 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Biogen.

What are Wall Street analysts saying about Biogen stock?

Here are some recent quotes from research analysts about Biogen stock:
  • 1. Cantor Fitzgerald analysts commented, ": Reiterate Neutral rating and $250 price target. Yesterday Novartis (NVS, NC) announced FDA approval of its oral S1P1 Mayzent (siponimod) in secondary progressive multiple sclerosis (SPMS), relapsing-remitting MS (RRMS), and clinically isolated syndrome using a priority voucher. We think this broad label is somewhat unexpected given that the pivotal study and regulatory filings were for SPMS patients, and a negative headline for competitors such as Biogen and possibly Celgene CELG, OW). With competitive efficacy and a cleaner label vs. NVS’ first gen S1P1 Gilenya, we think the key question is if and how quickly Mayzent can take share in RRMS post launch in early 2Q." (3/27/2019)
  • 2. HC Wainwright analysts commented, "Our PT of $363/share is based on a discounted cash flow analysis using a 10% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a commercial multiproduct biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing." (2/19/2019)

Has Biogen been receiving favorable news coverage?

Media stories about BIIB stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Biogen earned a news impact score of 1.8 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Biogen.

Are investors shorting Biogen?

Biogen saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 3,600,000 shares, a decrease of 16.9% from the January 15th total of 4,330,000 shares. Based on an average daily volume of 1,790,000 shares, the days-to-cover ratio is currently 2.0 days. Approximately 2.0% of the shares of the company are short sold. View Biogen's Current Options Chain.

Who are some of Biogen's key competitors?

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Netflix (NFLX), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Celgene (CELG), Tesla (TSLA), Amgen (AMGN), Micron Technology (MU), Walt Disney (DIS) and Intel (INTC).

Who are Biogen's key executives?

Biogen's management team includes the folowing people:
  • Mr. Michel Vounatsos, CEO & Director (Age 57)
  • Mr. Jeffrey D. Capello, Exec. VP & CFO (Age 54)
  • Ms. Susan H. Alexander, Exec. VP, Chief Legal Officer & Sec. (Age 62)
  • Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 50)
  • Dr. Paul F. McKenzie, Exec. VP of Pharmaceutical Operations & Technology (Age 53)

Who are Biogen's major shareholders?

Biogen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (4.56%), Renaissance Technologies LLC (2.63%), AQR Capital Management LLC (1.51%), Bank of New York Mellon Corp (1.22%), FMR LLC (0.81%) and Boston Partners (0.78%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michael D Ehlers, Michel Vounatsos and Robert W Pangia. View Institutional Ownership Trends for Biogen.

Which institutional investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, AQR Capital Management LLC, FMR LLC, State Street Corp, Assenagon Asset Management S.A., Massachusetts Financial Services Co. MA, Bank of Montreal Can and Virginia Retirement Systems ET AL. Company insiders that have sold Biogen company stock in the last year include Brian S Posner and Robert W Pangia. View Insider Buying and Selling for Biogen.

Which institutional investors are buying Biogen stock?

BIIB stock was acquired by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Renaissance Technologies LLC, Los Angeles Capital Management & Equity Research Inc., Bank of New York Mellon Corp, Fred Alger Management LLC, First Trust Advisors LP, Samlyn Capital LLC and Marshall Wace North America L.P.. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $333.00.

How big of a company is Biogen?

Biogen has a market capitalization of $57.96 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.View Additional Information About Biogen.

What is Biogen's official website?

The official website for Biogen is http://www.biogen.com/.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]


MarketBeat Community Rating for Biogen (NASDAQ BIIB)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,580 (Vote Outperform)
Underperform Votes:  1,006 (Vote Underperform)
Total Votes:  2,586
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe BIIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: What causes a recession?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel